Payment overview · 2025
General Payments
$234.44
11 reported records · 8 companies
Healthcare provider profile · identity verified
Andrew John Ridder, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SIOUX FALLS, SD · NPI 1285993253
Verified facts
What the public records show
CMS Open Payments records show Andrew John Ridder, M.D. received $234.44 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ongentys.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rytary by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.72 | 24.6% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $45.84 | 19.6% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.05 | 14.9% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $27.95 | 11.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.22 | 8.6% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.06 | 7.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.87 | 6.8% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $13.73 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.44 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $35.05 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $31.81 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ONGENTYS ongentys |
2025 | Ongentys | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 874 | 194 |
| Gabapentin | Gabapentin | 324 | 83 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 264 | 52 |
| Donepezil Hcl | Donepezil Hcl | 217 | 64 |
| Propranolol Hcl Er | Propranolol Hcl | 166 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 31 |
| Amantadine | Amantadine Hcl | 157 | 31 |
| Topiramate | Topiramate | 138 | 38 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 123 | 32 |
| Primidone | Primidone | 120 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 73 | 14 |
| Pregabalin | Pregabalin | 62 | 21 |
| Levetiracetam | Levetiracetam | 61 | 17 |
| Memantine Hcl | Memantine Hcl | 60 | 14 |
| Baclofen | Baclofen | 59 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 18 |
| Entacapone | Entacapone | 52 | 13 |
| Clonazepam | Clonazepam | 51 | 12 |
| Sertraline Hcl | Sertraline Hcl | 42 | 11 |
| Propranolol Hcl | Propranolol Hcl | 39 | 13 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Carbamazepine Er | Carbamazepine | 31 | suppressed |
| Gocovri | Amantadine Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Rytary | Carbidopa/Levodopa | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Austedo Xr | Deutetrabenazine | 20 | suppressed |
| Carbidopa | Carbidopa | 20 | suppressed |
| Ongentys | Opicapone | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Ingrezza | Valbenazine Tosylate | 17 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | 12 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 16 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Tetrabenazine | Tetrabenazine | 15 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.44 · 11 records | ABBVIE INC. | AMPYRA, BOTOX, CREXONT, INBRIJA, INFINITY, ONGENTYS, Ocrevus Zunovo, PONVORY, Symbravo, VYALEV, Xeomin, ZEPOSIA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ongentys play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error